Respironics

Vapotherm to Unveil Access365 Home Ventilation Solution at MEDTRADE

Retrieved on: 
Friday, March 15, 2024
Hypercapnia, Respironics, VAPO, Business, Patient, Mechanical ventilation, Spirometry, Business development, Quality of life, Respiratory disease, OTCQX, NIV, COPD, FDA, HME, Hospital

EXETER, N.H., March 15, 2024 /PRNewswire/ -- Vapotherm, Inc., (OTCQX: VAPO), ("Vapotherm" or the "Company") today announced the debut of its Access365™ Home Ventilation Solution at the upcoming MEDTRADE conference.

Key Points: 
  • EXETER, N.H., March 15, 2024 /PRNewswire/ -- Vapotherm, Inc., (OTCQX: VAPO), ("Vapotherm" or the "Company") today announced the debut of its Access365™ Home Ventilation Solution at the upcoming MEDTRADE conference.
  • Dr. Jessica Whittle, Chief Medical Officer of Vapotherm, emphasized the company's commitment to improving the lives of hypercapnic patients in the home.
  • "(1)
    The highly anticipated Access365 home ventilator will be unveiled at MEDTRADE Dallas on March 27th.
  • Joe Army, President and CEO of Vapotherm, underscored the significance of the solution, stating, "Vapotherm is committed to supporting patients both in and out of the hospital.

LONG ISLAND UNIVERSITY ANNOUNCES 2023 GEORGE POLK AWARDS IN JOURNALISM

Retrieved on: 
Monday, February 19, 2024
Hospital, Hamas, Long Island University, Animal, Injury, Commentary, Death, Justice Thomas, Health, New Yorker, Cipriani S.A., Firestone, Two weeks, Violence, CBS, Vice News, Television, Genocide, Ethics, Foreign, The New York Times, Radio, The Holocaust, Respironics, War, Photojournalism, Magazine, ProPublica, State, Interview, Father, Retirement, Gazette, Business, SpaceX, News, Digital media, CBS News, Supreme court, Insurance, Weeping Angel, Reuters, Disinformation, Medicine, AI, FDA, Food, Heart, Kid, KHOU-TV, Neuralink, Local, Risk, LIU, Crime, Patient, Family, Shadow, Musk, Privacy, Police, Assault, Justice

NEW YORK, Feb. 19, 2024 /PRNewswire/ -- Five recipients of the 2023 George Polk Awards, announced today by Long Island University, were for coverage of the Israel/Gaza and Russia/Ukraine wars in a year when the university is marking the 75th anniversary of one of American journalism's prized honors.

Key Points: 
  • NEW YORK, Feb. 19, 2024 /PRNewswire/ -- Five recipients of the 2023 George Polk Awards, announced today by Long Island University, were for coverage of the Israel/Gaza and Russia/Ukraine wars in a year when the university is marking the 75th anniversary of one of American journalism's prized honors.
  • The George Polk Awards were established in 1949 by LIU to commemorate George Polk, a CBS correspondent murdered in 1948 while covering the Greek civil war.
  • The awards, which place a premium on investigative and enterprising reporting that gains attention and achieves results, are conferred annually to honor special achievement in journalism.
  • At the same time, sixteen outstanding journalists whose careers reflect a commitment to deep investigative reporting will be honored as "George Polk laureates."

Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities

Retrieved on: 
Tuesday, February 6, 2024
CARE, Policy, AHI, Life, Splint (medicine), Nausea, Myotherapy, UnitedHealth Group, Irritation, Obstructive sleep apnea, Sleep, Nose, Patient, Safety, ResMed, FDA, CPAP, Respironics, PAP, Skin, Food, Mars, Therapy, Vomiting, Dizziness, Continuous positive airway pressure, Death, Headache, Health, Asthma, Pharmaceutical industry

In one market development, members of Vivos’ nationwide network of over 1,850 trained providers are actively treating current and former ResMed and Philips Respironics’ CPAP device users with Vivos CARE oral medical devices.

Key Points: 
  • In one market development, members of Vivos’ nationwide network of over 1,850 trained providers are actively treating current and former ResMed and Philips Respironics’ CPAP device users with Vivos CARE oral medical devices.
  • Vivos-trained providers currently treat failed HGNS cases using Vivos CARE oral medical devices and treatment plans.
  • Vivos believes most OSA patients seeking HGNS implants have high-moderate or severe OSA, leaving Vivos CARE oral medical devices as their only approved oral appliance therapy option.
  • We believe all of these factors create very significant revenue opportunities for us as we continue to spread the word about our product offerings.”

ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices

Retrieved on: 
Monday, January 29, 2024
Info, Sleep, Patient, PAP, Sleep apnea, Medicare, DDS, Food and Drug Administration, ASBA, Respironics, Obstructive sleep apnea, Food, CPAP, DSM, FDA, Paps, News, Diagnosis, OAT, Physician, Pharmaceutical industry

PLEASANTON, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA ) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced that the company is well-positioned to support patients with OSA and sleep physicians who can no longer access discontinued OSA devices.

Key Points: 
  • PLEASANTON, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA ) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced that the company is well-positioned to support patients with OSA and sleep physicians who can no longer access discontinued OSA devices.
  • Earlier in January, Philips Respironics announced the discontinuation of many devices used for the treatment and diagnosis of sleep apnea, including CPAP systems.
  • “Scientific data from over a dozen studies, including hundreds of patients, establish ProSomnus devices as safe, effective, and patient preferred.
  • “Philips has been a prominent player in the sleep health industry, providing innovative solutions for sleep apnea and other sleep disorders.

Philips delivers strong full-year results; agrees with FDA on terms of consent decree focused on Philips Respironics in the US

Retrieved on: 
Monday, January 29, 2024
Carbon, CDP, Non-invasive ventilation, Patient, JD, Informatics, MRI, Patient safety, Sleep, Health, Adjustment, Partnership, Share repurchase, Radiology, Google Images, Respironics, DJSI, Diagnosis, Bill, DOJ, S9000, Food, CPAP, EUR, USD, Carbon Disclosure Project, FDA, Personal care, Workforce, Treatment, NYU Langone Health, Growth, Medical imaging

1) Excluding provisions charged to sales of EUR 174 million in Q4 2023 mainly in connection with the Respironics consent decree.

Key Points: 
  • 1) Excluding provisions charged to sales of EUR 174 million in Q4 2023 mainly in connection with the Respironics consent decree.
  • We are fully committed to complying with the consent decree, which is an important step and provides a clear path forward.
  • The consent decree primarily focuses on Philips Respironics’ business operations in the US.
  • *) Excluding provisions charged to sales of EUR 174 million in Q4 2023 mainly in connection with the Respironics consent decree.

Settlement Administrator Angeion Group Announces Proposed Settlement in In Re Philips Recalled CPAP, Bi-Level PAP, and Mechanical Ventilator Products Litigation Class Action

Retrieved on: 
Thursday, January 11, 2024
Notice, Non-invasive ventilation, Device, Documentation, Payment, User, Respironics, Settlement, BIPAP, Grant Street, Court, CPAP, Ventilator, Joseph, Vexatious litigation, Hearing, Motion, Service award, Health insurance

PHILADELPHIA, Jan. 11, 2024 /PRNewswire/ -- A proposed Settlement of Economic Loss Claims has been reached in a U.S. class action lawsuit against Defendants Philips RS North America LLC ("Philips RS"), Koninklijke Philips N.V., Philips North America LLC, Philips Holding USA, Inc., and Philips RS North America Holding Corporation (collectively, the "Philips Defendants"), related to CPAP, BiPAP and ventilator devices sold in the United States between 2008 and 2021 that Philips RS recalled beginning in June 2021.  Plaintiffs in this lawsuit allege that the particular type of noise-reducing foam used in the recalled devices was defective. The Settlement is intended to resolve Economic Loss Claims only and does not affect or release any claims for personal injuries or medical monitoring relief.

Key Points: 
  • If You Paid For A Philips CPAP, BIPAP, Or Ventilator That Was Recalled By Philips RS North America LLC Beginning in June 2021, A Class Action Settlement May Affect Your Legal Rights.
  • Plaintiffs in this lawsuit allege that the particular type of noise-reducing foam used in the recalled devices was defective.
  • The Settlement is intended to resolve Economic Loss Claims only and does not affect or release any claims for personal injuries or medical monitoring relief.
  • You may be eligible to receive a payment if you paid for a Philips Respironics CPAP, BiPAP, or Ventilator that was recalled.

Respiratory Disease Testing Market Size & Trends Analysis 2023 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 28, 2023
Health, General Health, COPD, Prevalence, Medtronic, BD (company), Application, Respiratory disease, Patient, Occupational lung disease, Airway management, USD, Chronic obstructive pulmonary disease, CareFusion, CT scan, Diagnosis, Growth, Respironics, Asthma, NIV, Medical device, Pharmaceutical industry, Medical imaging

The "Respiratory Disease Testing Market Size, Share & Trends Analysis Report By Product (Imaging Tests, Respirometers, Blood Gas Tests), By End-use, By Application, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Respiratory Disease Testing Market Size, Share & Trends Analysis Report By Product (Imaging Tests, Respirometers, Blood Gas Tests), By End-use, By Application, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global respiratory disease testing market size is expected to reach USD 7.75 billion by 2030, registering a CAGR of 2.8% from 2023 to 2030
    The market is driven by the rising prevalence of respiratory diseases.
  • Along with technological advancements, use of digital radiography (X-ray) and advanced portable spirometers is gaining momentum in the respiratory disease testing/diagnostics market.
  • These players are strong brands in the market as they have elaborate product portfolios in respiratory disease diagnostics market

Settlement Administrator Angeion Group Announces Proposed Settlement in In Re Philips Recalled CPAP, Bi-Level PAP, and Mechanical Ventilator Products Litigation Class Action

Retrieved on: 
Monday, December 11, 2023
Grant Street, BIPAP, Respironics, Ventilator, Device, Notice, Payment, User, Documentation, Non-invasive ventilation, Vexatious litigation, CPAP, Service award, Joseph, Settlement, Tobacco Master Settlement Agreement, Hearing, Court, Motion, Tobacco, Pharmaceutical industry, Online shopping, Health insurance

PHILADELPHIA, Dec. 11, 2023 /PRNewswire/ -- A proposed Settlement of Economic Loss Claims has been reached in a U.S. class action lawsuit against Defendants Philips RS North America LLC ("Philips RS"), Koninklijke Philips N.V., Philips North America LLC, Philips Holding USA, Inc., and Philips RS North America Holding Corporation (collectively, the "Philips Defendants"), related to CPAP, BiPAP and ventilator devices sold in the United States between 2008 and 2021 that Philips RS recalled beginning in June 2021.  Plaintiffs in this lawsuit allege that the particular type of noise-reducing foam used in the recalled devices was defective. The Settlement is intended to resolve Economic Loss Claims only and does not affect or release any claims for personal injuries or medical monitoring relief.

Key Points: 
  • If You Paid For A Philips CPAP, BIPAP, Or Ventilator That Was Recalled By Philips RS North America LLC Beginning in June 2021, A Class Action Settlement May Affect Your Legal Rights.
  • Plaintiffs in this lawsuit allege that the particular type of noise-reducing foam used in the recalled devices was defective.
  • The Settlement is intended to resolve Economic Loss Claims only and does not affect or release any claims for personal injuries or medical monitoring relief.
  • You may be eligible to receive a payment if you paid for a Philips Respironics CPAP, BiPAP, or Ventilator that was recalled.

Settlement Administrator Angeion Group Announces Proposed Settlement in In Re Philips Recalled CPAP, Bi-Level PAP, and Mechanical Ventilator Products Litigation Class Action

Retrieved on: 
Monday, December 11, 2023
Grant Street, BIPAP, Respironics, Ventilator, Device, Notice, Payment, User, Documentation, Non-invasive ventilation, Vexatious litigation, CPAP, Service award, Joseph, Settlement, Tobacco Master Settlement Agreement, Hearing, Court, Motion, Tobacco, Pharmaceutical industry, Online shopping, Health insurance

PHILADELPHIA, Dec. 11, 2023 /PRNewswire/ -- A proposed Settlement of Economic Loss Claims has been reached in a U.S. class action lawsuit against Defendants Philips RS North America LLC ("Philips RS"), Koninklijke Philips N.V., Philips North America LLC, Philips Holding USA, Inc., and Philips RS North America Holding Corporation (collectively, the "Philips Defendants"), related to CPAP, BiPAP and ventilator devices sold in the United States between 2008 and 2021 that Philips RS recalled beginning in June 2021.  Plaintiffs in this lawsuit allege that the particular type of noise-reducing foam used in the recalled devices was defective. The Settlement is intended to resolve Economic Loss Claims only and does not affect or release any claims for personal injuries or medical monitoring relief.

Key Points: 
  • If You Paid For A Philips CPAP, BIPAP, Or Ventilator That Was Recalled By Philips RS North America LLC Beginning in June 2021, A Class Action Settlement May Affect Your Legal Rights.
  • Plaintiffs in this lawsuit allege that the particular type of noise-reducing foam used in the recalled devices was defective.
  • The Settlement is intended to resolve Economic Loss Claims only and does not affect or release any claims for personal injuries or medical monitoring relief.
  • You may be eligible to receive a payment if you paid for a Philips Respironics CPAP, BiPAP, or Ventilator that was recalled.

Philips delivers strong sales growth, profitability and cash flow; raises full-year outlook

Retrieved on: 
Monday, October 23, 2023
Adjustment, MDL, FDA, Intelligence, ECG, Health, Treatment, Workforce, Carbon, Philips, EBITA, Software, Justice, Comparable, Growth, Personal health record, Diagnosis, Informatics, Surgeon, Hospital, EUR, Share repurchase, Respironics, Sonicare, Algorithm, AI, Investment, Ali Baba, Patient, Patient safety, Bed, Service, Vanderbilt University Medical Center, Film industry, Medical device, Pharmaceutical industry, Video game, Nursing

Adjusted EBITA increased to EUR 457 million, or 10.2% of sales, mainly driven by increased sales, pricing and productivity measures.

Key Points: 
  • Adjusted EBITA increased to EUR 457 million, or 10.2% of sales, mainly driven by increased sales, pricing and productivity measures.
  • Comparable order intake (the order book covers around 40% of Group sales) was 9% lower than in Q3 2022.
  • Connected Care comparable sales increased 10% in the quarter, with double-digit growth in Monitoring and mid-single-digit growth in Enterprise Informatics.
  • Philips launched its ambulatory monitoring offering in Japan, combining Philips ePatch Holter monitors with ECG analysis through AI and advanced algorithms.